JUN 22, 2020 3:36 PM PDT

MDMA Has Long-Term Benefits Against PTSD

WRITTEN BY: Annie Lennon

Researchers have shown that MDMA-assisted psychotherapy has therapeutic effects that last over a year in treating post-traumatic stress disorder (PTSD). 

The new paper explores the long-term outcomes for people a year after completing MDMA psychotherapies. Comprising follow-up data from six previous trials, all in all, the researchers gathered data on around 100 patients. 

Participants in each trial underwent two to three therapy sessions with active doses of MDMA (75-125mg) alongside additional regular psychotherapy sessions. Their PTSD symptoms were measured using the Clinician-Administered PTSD Scale for DSM IV at baseline either one or two months following their last MDMA session, and then at least 12 months after that. Each participant also filled in a long-term follow-up survey. 

At the first follow-up, the researchers noted that 56% of the cohort no longer met the clinical criteria for PTSD. However, after the second follow-up, they found that participants tended to continue to improve over the year. This meant that 12 months on from the MDMA-sessions, 67% of the cohort no longer met the criteria for PTSD. 

The researchers also noted that after treatment, patients tended to have fewer suicidal thoughts and general PTSD symptoms. Their data also suggested that MDMA therapy does not lead to MDMA abuse nor any other substance abuse. 

"These long-term follow-up findings show that once people with PTSD learn that they can productively process traumatic memories instead of suppressing them, they can continue to heal themselves even after they have stopped receiving MDMA-assisted psychotherapy," says Rick Doblin, one of the authors of the study. 

Following the success of these Phase II trials, MDMA-assisted therapy is now in Phase III human trials for severe, treatment-resistant PTSD, with US Food and Drug Administration (FDA) approval expected in 2022. 

Meanwhile, due to the effectiveness of the treatment, earlier this year, the FDA approved it for Expanded Access, allowing select patients to access the procedure before it has full-market approval. 


Sources: New Atlas, Springer,

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 10, 2020
Cannabis Sciences
Cannabis Temporarily Relieves PTSD Symptoms
JUN 10, 2020
Cannabis Temporarily Relieves PTSD Symptoms
PTSD (Post Traumatic Stress Disorder) is a mental disorder characterized by flashbacks, nightmares, and severe anxiety f ...
JUN 12, 2020
Technology
How A Computer Sea Slug Can Get Addicted To A Drug
JUN 12, 2020
How A Computer Sea Slug Can Get Addicted To A Drug
Sea slugs have long been used to study brain models especially in research concerned with memory and learning. Now, rese ...
JUN 25, 2020
Cannabis Sciences
Can CBD Oil Treat Eczema?
JUN 25, 2020
Can CBD Oil Treat Eczema?
Around 30% of Americans are affected by eczema, a common condition known to cause dry skin, itching, irritation, and inf ...
JUN 25, 2020
Cell & Molecular Biology
Peptide Made by Marine Worms Can Destroy Multidrug-Resistant Bacteria
JUN 25, 2020
Peptide Made by Marine Worms Can Destroy Multidrug-Resistant Bacteria
Drug-resistant bacteria pose a serious threat to public health, and scientists have been searching for new antibiotics t ...
JUL 05, 2020
Neuroscience
Iron Build-up in Brain Linked to Alzheimer's
JUL 05, 2020
Iron Build-up in Brain Linked to Alzheimer's
Researchers from the Medical University of Graz in Austria have found a link between the build-up of iron in the brain&# ...
JUL 20, 2020
Technology
Robots as Models for Medicated Chewing Gum
JUL 20, 2020
Robots as Models for Medicated Chewing Gum
A robot with the ability to chew can provide useful insights on medicated chewing gum for pharmaceutical companies. The ...
Loading Comments...